Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy
Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy
复制标题
DOI：
10.1111/j.1751-0813.2005.tb15626.x
复制
发表时间：
2005-06-01
影响因子：
1.1
通讯作者：
Emms, SG
中科院分区：
文献类型：
--
作者：
Emms, SG
对作者1989年7月至2002年7月期间的临床记录进行了一项无肺转移的肛门囊肿瘤的回顾性研究，以确定对手术和美法仑化疗治疗的反应。在21只患有肛囊肿瘤的狗中，19只患有肛囊起源的顶泌腺癌，1只患有良性乳头状囊腺瘤，另1只患有恶性黑色素瘤。19只犬中有2只患有双侧肛门囊腺癌。19只患肛囊起源顶泌腺癌的狗中有10只有腰下淋巴结病。5只狗被它们的主人排除在推荐的治疗之外。对14只狗的肛囊源性顶泌腺癌进行了手术减瘤和美法仑化疗。14只犬中有7只存在区域淋巴结转移。所有14只犬均通过局部切除肛囊进行细胞减灭术，同时切除7只存在区域淋巴结转移的犬的腰下腹膜后淋巴结。患有腰下淋巴结转移的犬的中位生存时间为20个月，而患有局限于肛门囊的肿瘤的犬的中位生存时间为29.3个月。有腰椎下转移的狗与没有转移的狗的中位生存期没有差异。这项研究表明，当与细胞减灭术联合使用时，美法仑在治疗患有肛门囊腺癌的犬中具有作用，与先前发表的治疗方案相比，治疗存活时间和原发性肿瘤的局部复发率有利。
A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy. Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma. Two of the 19 dogs had bilateral anal sac adenocarcinomas. Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.Five dogs were excluded by their owners from recommended treatment. Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan. Seven of the 14 dogs had regional lymph node metastases. Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases. The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months. There was no difference in median survival of those dogs with sublumbar metastases compared to those without. This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.